Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Govt’s Economic Security Panel Discusses Plan for Supply Chain Survey
September 16, 2022
- MHLW to Submit Bill for Integrating Drug Supply Info in Extraordinary Diet Session: Official
September 15, 2022
- MHLW to Simplify Optimal-Use Guidelines for Drugs after Reexamination Period
September 15, 2022
- Contraindication Lifted for Concurrent Use of Adempas and HIV Protease Inhibitors
September 14, 2022
- Japan OKs Omicron COVID-19 Vaccines from Pfizer, Moderna
September 13, 2022
- MHLW Panel Recognizes 2 More Deaths Linked to COVID Jabs
September 13, 2022
- MHLW to Survey Impact of Price Surge, FX on Drugs with High Need for Stable Supply
September 13, 2022
- MHLW Panels’ Decision to Put a Hold on Shionogi’s COVID Pill Based on Regulatory Science: Official
September 12, 2022
- LDP Project Team Proposes Deeper Discussions on Structural Drug Pricing Issues
September 12, 2022
- Govt Laments AnGes’ Aborted COVID Vaccine Project, Renews Pledge to Back Potential Seeds
September 12, 2022
- PMDA Reviewing New Safety Risks for Itraconazole, I/O Drugs and More
September 12, 2022
- PMDA Sets 1st “GMP Roundtable” with Academia, Industry in November
September 12, 2022
- Japan to End Govt-Controlled Supply of Lagevrio on Sept. 15: MHLW
September 12, 2022
- Japan to Boost Number of HPV Vaccination Base Hospitals
September 9, 2022
- What Is Seen as New Omicron Variant Detected in Japan: NIID
September 9, 2022
- LDP Group Urges Thorough Discussions on New Data for Shionogi COVID Pill Once Out
September 8, 2022
- Pfizer/Moderna’s Omicron Vaccines on Japan Panel Agenda on Sept. 12
September 8, 2022
- Japan to Roll Out Pilot Program for SaMD Priority Review System
September 7, 2022
- Ultrasound Dementia Therapy Machine in Line for First Sakigake Device Designation, Japan Submission Eyed in 2025
September 6, 2022
- MHLW Study Group to Ponder Support Measures for Stable Generic Supplies
September 6, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…